- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01137292
Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection (Ve-RIFI)
31. august 2011 opdateret af: Pfizer
Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-Comparative Study
Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections.
The study is conducted in Slovakia only.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
177
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
2 år og ældre (Barn, Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Male or female patients older than 2 years with invasive fungal infections.
Beskrivelse
Inclusion Criteria:
- Male or female patient of age 2 years or older.
- High-risk patients with proven, probable or possible invasive fungal infection (IFI) according to the EORTC/MSG criteria.
- Patients indicated for secondary prophylaxis of invasive aspergillosis.
Exclusion Criteria:
- Patients with known hypersensitivity to voriconazole or to any of the excipients.
- Patients with contraindicated concomitant medications according to the SmPC.
- Children less than 2 years of age.
- Pregnancy and lactation.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Active Treatment
Patients who are eligible for voriconazole treatment according to their physician decision.
|
The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity.
The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation.
According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv.
every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID.
For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary.
Depending on the formulation, the daily dosage should be in children 7 mg/kg iv.
BID or 200 mg of voriconazole orally BID.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Clinical and/or Mycological Efficacy by Response at the End of Treatment (EOT) Visit
Tidsramme: up to 2 weeks (EOT visit)
|
Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, and no mycological culture performed.
Participants could have had more than one response.
Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines.
|
up to 2 weeks (EOT visit)
|
Number of Participants With Clinical and/or Mycological Efficacy by Response at the Test-of-Cure Visit
Tidsramme: more than 2 weeks (Test-of-Cure visit)
|
Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, no mycological culture performed, death, and lost from follow-up.
Participants could have had more than one response.
Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines.
|
more than 2 weeks (Test-of-Cure visit)
|
Number of Participants With Investigator's Satisfaction With the Efficacy of Voriconazole Assessment at the EOT Visit
Tidsramme: up to 2 weeks (EOT visit)
|
Investigator's Satisfaction Responses: very good, good, moderate, poor.
Responses were based on the investigator's judgement.
|
up to 2 weeks (EOT visit)
|
Number of Participants With Investigator's Satisfaction With the Tolerability of Voriconazole Assessment at the EOT Visit
Tidsramme: up to 2 weeks (EOT visit)
|
Investigator's Satisfaction Responses: very good, good, moderate, poor.
Responses were based on the investigator's judgement.
|
up to 2 weeks (EOT visit)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2007
Primær færdiggørelse (Faktiske)
1. november 2009
Studieafslutning (Faktiske)
1. november 2009
Datoer for studieregistrering
Først indsendt
2. juni 2010
Først indsendt, der opfyldte QC-kriterier
3. juni 2010
Først opslået (Skøn)
4. juni 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
2. september 2011
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
31. august 2011
Sidst verificeret
1. august 2011
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Sygdomsegenskaber
- Bakterielle infektioner og mykoser
- Infektioner
- Overførbare sygdomme
- Mykoser
- Invasive svampeinfektioner
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Hormoner, hormonsubstitutter og hormonantagonister
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Hormonantagonister
- Antifungale midler
- Steroidsyntesehæmmere
- 14-alfa-demethylasehæmmere
- Voriconazol
Andre undersøgelses-id-numre
- A1501082
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Invasive svampeinfektioner
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universitätsklinikum Hamburg-EppendorfRekrutteringSerratus anterior plane blok | Minimal invasiv hjertekirurgi | Minimal invasiv hjertekirurgi MitralklapkirurgiTyskland
-
Algemeen Ziekenhuis Maria MiddelaresAfsluttetUdskiftning af aortaklap | Mitralklapkirurgi | Minimal invasiv hjertekirurgi | Minimal invasiv direkte koronararterie bypassBelgien
-
Melbourne HealthMerck Sharp & Dohme LLCRekrutteringSvampeinfektion | Farmakokinetik | Invasiv aspergillose | Profylakse | Invasive candidiaser | Posaconazol | Invasiv mykoseAustralien
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Children...AfsluttetPædiatrisk invasiv candidiasisForenede Stater, Colombia, Canada, Indien, Saudi Arabien, Grækenland, Italien, Spanien
-
CSPC Ouyi Pharmaceutical Co., Ltd.Ikke rekrutterer endnuInvasiv aspergillose | Invasiv candidiasisKina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UkendtInvasiv aspergillose | Invasiv candidiasis
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de...RekrutteringIkke-invasiv ventilationSpanien
-
Felix JF HerthDLR German Aerospace Center; University Hospital Heidelberg; Federal Joint... og andre samarbejdspartnereRekrutteringFravænning | Invasiv ventilationTyskland
Kliniske forsøg med voriconazole (VFEND®)
-
PfizerUniversity of Southern CaliforniaAfsluttet
-
PfizerAfsluttetCandidæmi | CandidiasisForenede Stater
-
Seoul National University HospitalAfsluttetSunde frivilligeKorea, Republikken
-
PfizerAfsluttet
-
Chong Kun Dang PharmaceuticalAfsluttetSvampeinfektioner | Candida infektioner | Aspergillus infektionerKorea, Republikken
-
PfizerAfsluttetAntifungal profylakse af invasive svampeinfektionerCanada, Spanien, Grækenland, Frankrig, Portugal, Det Forenede Kongerige, Tjekkiet, Egypten, Jordan, Den Russiske Føderation, Schweiz, Kalkun
-
PfizerAfsluttet
-
PfizerAfsluttet
-
Zambon SpAAfsluttetAllergisk bronkopulmonal aspergilloseDet Forenede Kongerige
-
Manjunath Prakash PaiPfizer; TKL Research, Inc.Afsluttet